ophthalmology | pharmaphorum

Skip to main content

Wednesday 20 May 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

ophthalmology

News

spark-therapeutics-big

FDA makes history, approving Spark's eye gene therapy

Christmas has come a few days early for Spark Therapeutics after the FDA approved its ground-breaking gene therapy for a rare eye disease.

News

eye

Regeneron/Bayer axe eye combination drug

Phase 2 data showed no improvement over Eylea

Partner Content

Oph

Partner Content

Europe’s Leading Ophthalmic Conference is Just 1 week away

Ophthalmic Drugs

Partner Content

www.ophthalmicdrugs.com/pph

Partner Content

SMi’s Europe’s Leading Ophthalmic Conference is only 2 weeks...

Ophthalmic Drugs

News

eye

FDA approves Valeant eye drug after manufacturing delay

Regulator backs potential blockbuster ophthalmology drug

Views & Analysis

Eye marketing future 600

Learning from a successful ophthalmology brand launch

Applying learnings from a successful ophthalmology brand launch to other therapy areas and pharmaceutical brands.

Load more results

Editor's Picks

'Seismic shift' as obesity overtakes cancer for R&D returns

Bayer returns to M&A with $2.45bn Perfuse Therapeutics deal

Lilly inflates US facility investment spending by $4.5bn

Roche buys AI-powered diagnostics player PathAI

Danco fights back after US court curbs abortion pill access

News

Pfizer takes 25-valent Prevnar follow-up into phase 3

Pfizer takes 25-valent Prevnar follow-up into phase 3

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company